These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
735 related articles for article (PubMed ID: 32727810)
1. Small molecule AZD4635 inhibitor of A Borodovsky A; Barbon CM; Wang Y; Ye M; Prickett L; Chandra D; Shaw J; Deng N; Sachsenmeier K; Clarke JD; Linghu B; Brown GA; Brown J; Congreve M; Cheng RK; Dore AS; Hurrell E; Shao W; Woessner R; Reimer C; Drew L; Fawell S; Schuller AG; Mele DA J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727810 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of Combination Strategies for the A Voronova V; Peskov K; Kosinsky Y; Helmlinger G; Chu L; Borodovsky A; Woessner R; Sachsenmeier K; Shao W; Kumar R; Pouliot G; Merchant M; Kimko H; Mugundu G Front Immunol; 2021; 12():617316. PubMed ID: 33737925 [TBL] [Abstract][Full Text] [Related]
3. Overcoming high level adenosine-mediated immunosuppression by DZD2269, a potent and selective A2aR antagonist. Bai Y; Zhang X; Zheng J; Liu Z; Yang Z; Zhang X J Exp Clin Cancer Res; 2022 Oct; 41(1):302. PubMed ID: 36229853 [TBL] [Abstract][Full Text] [Related]
4. Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103 Zhou Y; Slone N; Chrisikos TT; Kyrysyuk O; Babcock RL; Medik YB; Li HS; Kleinerman ES; Watowich SS J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32273347 [TBL] [Abstract][Full Text] [Related]
5. Non-small Cell Lung Cancer Cells Modulate the Development of Human CD1c Lu Y; Xu W; Gu Y; Chang X; Wei G; Rong Z; Qin L; Chen X; Zhou F Front Immunol; 2019; 10():2829. PubMed ID: 31921114 [TBL] [Abstract][Full Text] [Related]
6. Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition. Salmon H; Idoyaga J; Rahman A; Leboeuf M; Remark R; Jordan S; Casanova-Acebes M; Khudoynazarova M; Agudo J; Tung N; Chakarov S; Rivera C; Hogstad B; Bosenberg M; Hashimoto D; Gnjatic S; Bhardwaj N; Palucka AK; Brown BD; Brody J; Ginhoux F; Merad M Immunity; 2016 Apr; 44(4):924-38. PubMed ID: 27096321 [TBL] [Abstract][Full Text] [Related]
7. A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment. Mediavilla-Varela M; Castro J; Chiappori A; Noyes D; Hernandez DC; Allard B; Stagg J; Antonia SJ Neoplasia; 2017 Jul; 19(7):530-536. PubMed ID: 28582704 [TBL] [Abstract][Full Text] [Related]
8. CD103 (αE Integrin) Undergoes Endosomal Trafficking in Human Dendritic Cells, but Does Not Mediate Epithelial Adhesion. Swain S; Roe MM; Sebrell TA; Sidar B; Dankoff J; VanAusdol R; Smythies LE; Smith PD; Bimczok D Front Immunol; 2018; 9():2989. PubMed ID: 30622531 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models. Leone RD; Sun IM; Oh MH; Sun IH; Wen J; Englert J; Powell JD Cancer Immunol Immunother; 2018 Aug; 67(8):1271-1284. PubMed ID: 29923026 [TBL] [Abstract][Full Text] [Related]
13. Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors. Lim EA; Bendell JC; Falchook GS; Bauer TM; Drake CG; Choe JH; George DJ; Karlix JL; Ulahannan S; Sachsenmeier KF; Russell DL; Moorthy G; Sidders BS; Pilling EA; Chen H; Hattersley MM; Das M; Kumar R; Pouliot GP; Patel MR Clin Cancer Res; 2022 Nov; 28(22):4871-4884. PubMed ID: 36044531 [TBL] [Abstract][Full Text] [Related]
14. The Emerging Role of CD8 Corgnac S; Boutet M; Kfoury M; Naltet C; Mami-Chouaib F Front Immunol; 2018; 9():1904. PubMed ID: 30158938 [TBL] [Abstract][Full Text] [Related]
15. Liver-resident CD103+ dendritic cells prime antiviral CD8+ T cells in situ. Krueger PD; Kim TS; Sung SS; Braciale TJ; Hahn YS J Immunol; 2015 Apr; 194(7):3213-22. PubMed ID: 25712214 [TBL] [Abstract][Full Text] [Related]
16. Co-immunization with L-Myc enhances CD8 Chai D; Zhang Z; Jiang N; Ding J; Qiu D; Shi SY; Wang G; Fang L; Li H; Tian H; Yang J; Zhang Q; Zheng J Cancer Sci; 2021 Sep; 112(9):3469-3483. PubMed ID: 34157192 [TBL] [Abstract][Full Text] [Related]
17. CD103 Miao X; Chen Y; Hao K; Zheng M; Chen B; Li K; Wang Y; Zhang W; Zhang Y; Mou X; Jiang S; Wang Z Oncol Res; 2018 Mar; 26(2):173-182. PubMed ID: 28109087 [TBL] [Abstract][Full Text] [Related]
18. Retinoic acid-loaded liposomes induce human mucosal CD103 Nagy NA; Hafkamp FMJ; Sparrius R; Bas R; Lozano Vigario F; van Capel TMM; van Ree R; Geijtenbeek TBH; Slütter B; Tas SW; de Jong EC Eur J Immunol; 2024 May; 54(5):e2350839. PubMed ID: 38430190 [TBL] [Abstract][Full Text] [Related]
19. MyD88 Signaling Regulates Steady-State Migration of Intestinal CD103+ Dendritic Cells Independently of TNF-α and the Gut Microbiota. Hägerbrand K; Westlund J; Yrlid U; Agace W; Johansson-Lindbom B J Immunol; 2015 Sep; 195(6):2888-99. PubMed ID: 26259586 [TBL] [Abstract][Full Text] [Related]
20. Genetic and pharmacological targeting of A2a receptor improves function of anti-mesothelin CAR T cells. Masoumi E; Jafarzadeh L; Mirzaei HR; Alishah K; Fallah-Mehrjardi K; Rostamian H; Khakpoor-Koosheh M; Meshkani R; Noorbakhsh F; Hadjati J J Exp Clin Cancer Res; 2020 Mar; 39(1):49. PubMed ID: 32151275 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]